Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
CA9-Targeted PET Imaging for Noninvasive Discrimination of Clear Cell Renal Cell Carcinoma and Associated Tumor Biological Features.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Kailei, Cheng Sixuan, Shi Jian, Liu Ruijie, Wu Yilong, Zheng Xin, Song Xinlun, Zhang Yunxuan, Liu Lei, Wei Zhihao, Wang Qi, Li Xinwei, Dong Zirui, Liu Yuenan, Yang Hongmei, Lan Xiaoli, Qin Chunxia, Jiang Dawei, Wang Keshan, Zhang Xiaoping
Аннотация
PURPOSE: Clear cell renal cell carcinoma (ccRCC) is biologically distinct from non-clear cell renal cell carcinoma (nccRCC), and shows marked intratumoral heterogeneity, yet current imaging modalities lack the ability to noninvasively distinguish histologic subtypes or capture tumor biological features in vivo.
EXPERIMENTAL DESIGN: An integrative analysis combines CA9-targeted positron emission tomography (PET) imaging with multi-omic analyses, histopathological validation, and functional assessment using patient-derived xenograft (PDX) models. Clinical CA9-targeted PET imaging is evaluated in patients with renal masses and examined alongside 18F-FDG PET.
RESULTS: CA9 is preferentially enriched in ccRCC tumor cells with low background expression in normal kidney tissue. CA9-targeted PET imaging shows potential for noninvasive discrimination of ccRCC from nccRCC, including lesions with distinct histologies within individual patients. High CA9-targeted PET uptake is associated with PBRM1 loss-of-function alterations, immune pathway suppression with reduced B cell infiltration, metabolic alterations, and enhanced angiogenic activity. Single-cell and spatial analyses support endothelial enrichment and angiogenesis-associated programs in CA9-high regions. CA9-high PDX models showed greater tumor growth inhibition under axitinib treatment.
CONCLUSIONS: CA9-targeted PET provides proof-of-concept evidence for noninvasive discrimination of ccRCC and associated angiogenic and tumor biological features, warranting prospective validation.
EXPERIMENTAL DESIGN: An integrative analysis combines CA9-targeted positron emission tomography (PET) imaging with multi-omic analyses, histopathological validation, and functional assessment using patient-derived xenograft (PDX) models. Clinical CA9-targeted PET imaging is evaluated in patients with renal masses and examined alongside 18F-FDG PET.
RESULTS: CA9 is preferentially enriched in ccRCC tumor cells with low background expression in normal kidney tissue. CA9-targeted PET imaging shows potential for noninvasive discrimination of ccRCC from nccRCC, including lesions with distinct histologies within individual patients. High CA9-targeted PET uptake is associated with PBRM1 loss-of-function alterations, immune pathway suppression with reduced B cell infiltration, metabolic alterations, and enhanced angiogenic activity. Single-cell and spatial analyses support endothelial enrichment and angiogenesis-associated programs in CA9-high regions. CA9-high PDX models showed greater tumor growth inhibition under axitinib treatment.
CONCLUSIONS: CA9-targeted PET provides proof-of-concept evidence for noninvasive discrimination of ccRCC and associated angiogenic and tumor biological features, warranting prospective validation.